Expression of Programmed Death Ligand 1 in Breast Cancer in Mexican Women
Pablo Jose Erraez-Jaramillo1, Evelyn Aguirre-Flores1, Luis Fernando Athie-Meza2
1Anatomic Pathology Research Unit, Medica Sur Hospital and Clinical Foundation, Mexico City, Mexico.
Background:
Breast cancer is one of the most common malignant forms of neoplasia worldwide; programmed death protein 1 (PD-1), an inhibitory receptor of T lymphocytes, and its ligand programmed death ligand 1 (PD-L1), play an important role in the ability of tumor cells to evade the host's immune system.
Methods:
We conducted a descriptive, observational study using retrospective data and an open evaluation using immunohistochemistry to determine the general prevalence of PD-L1 expression in 63 women with breast cancer who underwent a modified radical mastectomy, or quadrantectomy, with axillary lymph node removal.
Results:
The prevalence of PD-L1 expression was 32% in patients with breast cancer treated with radical mastectomy. PD-L1 expression was higher in patients with large tumor size (19% for pT1, 37% for pT2, 50% for pT3, and 100% for pT4), metastasis in regional lymph nodes (25% for N0, 38% for N1, 75% for pN2, and 38% for pN3), and higher histological grade carcinoma (0% for grade 1, 23% for grade 2, and 50% for grade 3).
Conclusions:
These findings suggest that PD-L1 expression is heterogeneous in breast cancer tumors and that its expression varies highly in tumor regions over time. The evaluation of PD-L1 expression is significant, because of the therapeutical implications that could improve the outcomes and prognosis of these patients.
Insights
Programmed death ligand 1 (PD-L1) is expressed in 32% of breast cancers. Higher PD-L1 expression correlates with larger tumor size, lymph node metastasis, and higher tumor grade, impacting treatment strategies.
Area of Science:
- Oncology
- Immunology
- Pathology
Background:
- Breast cancer is a prevalent malignancy globally.
- Programmed death protein 1 (PD-1) and its ligand PD-L1 are key regulators of immune evasion by tumor cells.
Purpose of the Study:
- To determine the prevalence of PD-L1 expression in breast cancer patients.
- To investigate the correlation between PD-L1 expression and clinicopathological features.
Main Methods:
- Descriptive, observational study with retrospective data.
- Immunohistochemistry used for PD-L1 expression evaluation.
- Study included 63 women with breast cancer.
Main Results:
- PD-L1 expression was detected in 32% of breast cancer patients.
- Expression levels increased with tumor size (pT1-pT4), lymph node metastasis (pN0-pN3), and histological grade (Grade 1-3).
Conclusions:
- PD-L1 expression in breast cancer is heterogeneous and varies over time.
- Evaluating PD-L1 expression is crucial for therapeutic implications and improving patient prognosis.
More Related Videos
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
02:23Abnormal Proliferation